title: Erythropoietin as adjuvant to pre-operative autologous blood donation in total hip arthroplasty: new algorithm for use.
abstract: Erythropoietin (rhEPO) has been used in different surgical procedures as a method for saving allogeneic blood, with variable efficacy. Forty consecutive patients entered the pre-operative autologous blood donation (PABD) program, and during donations hemoglobin fell below 115 g/l; they received rhEPO 40,000 U every week for three or four weeks (group 1). As control group, 35 consecutive patients who entered the PABD program were studied; during donations, hemoglobin levels in these patients fell below 115 g/l, but rhEPO was not administered (group 2). Pre-surgery hemoglobin levels were higher in patients who received rhEPO (134 g/l vs. 121 g/l; p<0.0002), and an average of 3.47 doses were administered. The number of transfused autologous units was 1.6 in group 1 and 2.1 in group 2 (p<0.05), while the number of allogeneic units was 0.9 and 0.1, respectively (p<0.0005), so that only 5% of patients treated with rhEPO required some allogeneic unit, as compared to 40% of those who did not receive rhEPO (p<0.0005). There were no relevant adverse effects, but in two patients from group 1, rhEPO treatment had to be discontinued because the level of hemoglobin exceeded 150 g/l. The mean duration of hospital admission was shorter in the patients who received rhEPO than in those who only underwent PABD (8 days vs. 11.8 days; NS). When adequately used, rhEPO is an effective and safe alternative to the use of allogeneic blood.
authors.affiliation: Department of Hematology, Hospital de Jarrio, SESPA, Spain. mvargasp@aehh.org
authors.forename: Manuel
authors.initials: M
authors.lastname: Vargas-Pabon
authors.forename: Ana
authors.initials: A
authors.lastname: Diaz-Trapiella
authors.forename: Miguel Jimenez
authors.initials: MJ
authors.lastname: Hurtado
authors.forename: Nicolas
authors.initials: N
authors.lastname: Diaz Varela
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Cerra Sabio
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage*; D000368:Aged; D000465:Algorithms; D019644:Arthroplasty, Replacement, Hip; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001804:Blood Transfusion, Autologous / Q000379:methods; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D000277:Adjuvants, Pharmaceutic; D011994:Recombinant Proteins; D004921:Erythropoietin